E-Mail
A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million of funding from UK Research and Innovation (UKRI).
The G2P-UK National Virology Consortium will study how mutations in the virus affect key outcomes such as how transmissible it is, the severity of COVID-19 it causes, and the effectiveness of vaccines and treatments.
The Consortium will bring together leading virologists from 10 research institutions . They will work alongside the COVID-19 Genomics UK (COG-UK) consortium, which plays a world-leading role in virus genome sequencing, and Public Health England to boost the UK s capacity to study newly identified virus variants and rapidly inform government policy.
Screening and Resistance
Hub), has received £2.5million to establish a national resource which will initially be dedicated to supporting and accelerating vital COVID-19 antiviral innovation drug translation.
The facility is funded by £2m from medical research charity LifeArc, with additional funding from the Medical Research Council. CVR CRUSH will be delivered by the University of Glasgow in collaboration with partners LifeArc and the University of Dundee Drug Discovery Unit.
Global control of the COVID-19 pandemic is dependent on the availability of effective medical treatments and vaccines. CVR CRUSH will help support the global scientific effort against the disease by providing a fully integrated hub for pre-clinical drug screening and resistance assays for SARS-CoV-2, the virus that causes COVID-19, as well as providing the same services for other dangerous and deadly viruses in high containment facilities.
New COVID-19 drug screening hub established in Scotland
7th January 2021
A new COVID-19 drug screening and resistance facility, funded by medical research charity LifeArc, has been established at the MRC-University of Glasgow Centre for Virus Research (CVR).
The project – COVID-19 Drug-Screening and Resistance Hub (CRUSH) – has been granted £2.5m to establish a hub dedicated to supporting and accelerating COVID-19 antiviral innovation drug translation.
It is funded by £2m from LifeArc plus additional funding from the Medical Research Council, with the hub set to be delivered by the University of Glasgow in Collaboration with LifeArc and the University of Dundee Drug Discovery Unit.
Glasgow University science hub established to screen Covid-19 drugs
A coronavirus sample is held at a laboratory in Glasgow (Andrew Milligan/PA)
A £2.5 million science hub is to be established at the University of Glasgow to screen treatments for Covid-19.
Crush (Covid-19 Drug-Screening and Resistance Hub) will investigate promising drugs for the virus.
It will also provide drug screening for other dangerous and deadly viruses in its high containment facilities.
Scientists at the hub will look to identify any possible drug and immune-resistant virus variants.
Research charity LifeArc has given £2 million to the project, with additional funds provided by the Medical Research Council.
Glasgow University science hub set up to screen Covid-19 drugs A new science hub is to be created at Glasgow University to screen treatments for coronavirus. The £2.5 million facility, named Crush (Covid-19 Drug-Screening and Resistance Hub), will investigate promising drugs for the virus. It will also provide drug screening for other dangerous and deadly viruses in its high containment facilities. Scientists at the hub will look to identify any possible drug and immune-resistant virus variants. Research charity LifeArc has given £2 million to the project, with additional funds provided by the Medical Research Council. It will be based at the MRC-University of Glasgow Centre for Virus Research (CVR) in partnership with the University of Dundee Drug Discovery Unit.